Does Sapropterin Work for PKU Patients?
Sapropterin dihydrochloride (Kuvan) helps a subset of phenylketonuria (PKU) patients by acting as a synthetic form of tetrahydrobiopterin (BH4), a cofactor that boosts phenylalanine hydroxylase (PAH) enzyme activity. This reduces blood phenylalanine (Phe) levels in BH4-responsive patients, who make up about 20-50% of those with PAH-deficient PKU.[1][2]
How Do Doctors Test for Responsiveness?
Patients undergo a BH4 loading test: they take sapropterin (typically 20 mg/kg/day) for 24-48 hours while monitoring blood Phe levels. A drop of 30% or more indicates responsiveness. Genetic testing for PAH mutations can predict response but isn't definitive.[1][3]
Who Benefits Most?
It works best in mild or moderate PKU (Phe levels 360-2000 μmol/L at diagnosis), children under 6, and those with specific PAH variants like p.R261Q. Non-responders, including most classic PKU cases (Phe >1200 μmol/L), see little effect and stick to low-Phe diets.[2][4]
What Do Clinical Trials Show?
Phase 3 trials (e.g., KUVAN-001) enrolled 90 responsive patients aged 4-12: sapropterin reduced mean Phe by 36% vs. placebo, allowing 61% to loosen dietary restrictions while staying below 360 μmol/L. Long-term data up to 6 years confirm sustained control in responders.[1][5]
What Side Effects Do Patients Report?
Common issues include headache (13%), runny nose (12%), and sore throat (10%), mostly mild. Rare serious risks: hypersensitivity (pharyngeal swelling) or hyperphenylalaninemia rebound if stopped abruptly. No increased cancer or neurocognitive risks in trials.[1][6]
How Does It Compare to Diet Alone?
Sapropterin expands protein intake (e.g., from 20g to 40g/day) and improves quality of life for responders, but diet remains essential. It doesn't replace low-Phe formula; non-responders or adults often need pegvaliase (Palynziq), an enzyme substitute.[2][7]
When Does Insurance Cover It and What's the Cost?
FDA-approved for PKU since 2007 (ages 1 month+ if responsive). Costs ~$100,000/year without aid; patient assistance programs cut it to $0 for eligible low-income users. Coverage requires confirmed response.[1][8]
Are There Upcoming Generics or Alternatives?
Patent expiry was 2020; authorized generics (e.g., from Ameda) launched 2022, dropping prices 80%+.[9] Alternatives: large neutral amino acids (LNAA) for mild cases, pegvaliase injections for adults unresponsive to BH4.
[1]: Kuvan Prescribing Information (FDA)
[2]: Vockley et al., Mol Genet Metab 2014
[3]: Blau et al., J Inherit Metab Dis 2010
[4]: Burton et al., Mol Genet Metab 2007
[5]: Levy et al., Lancet 2007
[6]: Kuvan Adverse Events (FDA)
[7]: Pegvaliase Label (FDA)
[8]: GoodRx Pricing Data
[9]: DrugPatentWatch.com - Sapropterin Patents